1. Home
  2. HKIT vs INM Comparison

HKIT vs INM Comparison

Compare HKIT & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HKIT

Hitek Global Inc.

HOLD

Current Price

$0.53

Market Cap

2.6M

Sector

Technology

ML Signal

HOLD

Logo InMed Pharmaceuticals Inc.

INM

InMed Pharmaceuticals Inc.

HOLD

Current Price

$1.57

Market Cap

2.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HKIT
INM
Founded
1996
1981
Country
China
Canada
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6M
2.1M
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
HKIT
INM
Price
$0.53
$1.57
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
19.2M
3.0M
Earning Date
04-24-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$4,942,633.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
7.50
52 Week Low
$0.03
$0.58
52 Week High
$8.80
$3.34

Technical Indicators

Market Signals
Indicator
HKIT
INM
Relative Strength Index (RSI) 47.88 65.92
Support Level N/A $1.09
Resistance Level $1.97 $1.95
Average True Range (ATR) 0.67 0.12
MACD -0.11 -0.03
Stochastic Oscillator 3.73 18.54

Price Performance

Historical Comparison
HKIT
INM

About HKIT Hitek Global Inc.

Hitek Global Inc is a provider of information technology consulting and solutions services. The company has two lines of business services to small and medium businesses, which consist of Anti-Counterfeiting Tax Control System tax devices, including Golden Tax Disk and printers, ACTCS services, and IT services; and services to large businesses, which include hardware sales and software sales. It generates revenues from Hardware and equipment sales, Tax services, and Software sales.

About INM InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.

Share on Social Networks: